GNLX · GENELUX Corp
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, has expressed substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 7, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-01 | Smither John W |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. The weighted average sale price for the transaction reported was $2.9082, and the range of prices were between $2.87 and $2.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
Common Stock
|
12,000 |
| 2026-06-16 | Groen Eric |
General Counsel |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter |
Common Stock
|
233,957 |
| 2026-06-16 | Pulisic Matthew |
Chief Financial Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter |
Common Stock
|
278,906 |
| 2026-06-16 | Smither John W |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. |
Common Stock
|
28,409 |
| 2026-06-16 | Mirabelli Mary |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. |
Common Stock
|
28,409 |
| 2026-06-16 | Tyree James L |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. |
Stock Option (Right to Buy)
|
31,566 |
| 2026-06-16 | Zindrick Thomas |
President and CEO |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter. Includes 1261 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026. |
Common Stock
|
730,601 |
| 2026-06-16 | Thomas John |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. |
Common Stock
|
28,409 |
| 2026-06-16 | Cappello Joseph |
Chief Technical Officer |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter. |
Common Stock
|
174,841 |
| 2026-06-16 | Tyree James L |
Director |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. |
Common Stock
|
28,409 |
| 2026-06-16 | Mirabelli Mary |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. |
Stock Option (Right to Buy)
|
31,566 |
| 2026-06-16 | Smither John W |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. |
Stock Option (Right to Buy)
|
31,566 |
| 2026-06-16 | Yu Yong |
SVP, Clinical Development |
Award↑
Filing footnotes — Common Stock (Direct)
Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter. |
Common Stock
|
119,318 |
| 2026-06-16 | Thomas John |
Director |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. |
Stock Option (Right to Buy)
|
31,566 |
| 2026-06-03 | Smalling Ralph |
Head of Regulatory |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. |
Common Stock
|
192 |
| 2026-06-01 | Thomas John |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2025. The weighted average sale price for the transaction reported was $2.9801, and the range of prices were between $2.94 and $3.05. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
Common Stock
|
10,000 |
| 2026-05-11 | Yu Yong |
SVP, Clinical Development |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. The weighted average sale price for the transaction reported was $2.9726, and the range of prices were between $2.95 and $3.02. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
Common Stock
|
605 |
| 2026-05-11 | Zindrick Thomas |
President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. The weighted average sale price for the transaction reported was $2.9398, and the range of prices were between $2.89 and $3.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
Common Stock
|
2,798 |
| 2026-05-11 | Cappello Joseph |
Chief Technical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. The weighted average sale price for the transaction reported was $2.9742, and the range of prices were between $2.96 and $3.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
Common Stock
|
605 |
| 2026-05-11 | Smalling Ralph |
Head of Regulatory |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. The weighted average sale price for the transaction reported was $2.9796, and the range of prices were between $2.97 and $2.98. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
Common Stock
|
270 |
| 2026-03-25 | Smalling Ralph |
Head of Regulatory |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. |
Common Stock
|
240 |
| 2026-03-24 | Cappello Joseph |
Chief Technical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. |
Common Stock
|
906 |
| 2026-03-24 | Zindrick Thomas |
President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. |
Common Stock
|
3,582 |
| 2026-03-24 | Smalling Ralph |
Head of Regulatory |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. |
Common Stock
|
345 |
| 2026-03-24 | Yu Yong |
SVP, Clinical Development |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. |
Common Stock
|
906 |
| 2026-03-02 | Thomas John |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2025. The weighted average sale price for the transaction reported was $2.8957, and the range of prices were between $2.82 and $3.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
Common Stock
|
10,000 |
| 2026-01-02 | Litten Jason |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The shares subject to the option will vest 25% on the first anniversary of the grant date, and the remaining shares will vest in 36 equal monthly installments thereafter. |
Stock Option (Right to Buy)
|
275,000 |
| 2026-01-02 | Litten Jason |
Chief Medical Officer |
Other↑
|
No Securities Owned
|
0 |
| 2025-12-05 | Smalling Ralph |
Head of Regulatory |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. The total shown in Column 5 takes into account the transactions reported on Forms 4 filed on August 29, 2025 and September 3, 2025. |
Common Stock
|
165 |
| 2025-12-01 | Thomas John |
Director |
Sell↓
Filing footnotes — Common Stock (Direct)
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 4, 2025. The weighted average sale price for the transaction reported was $5.0008, and the range of prices were between $4.73 and $5.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
Common Stock
|
10,000 |
| 2025-11-17 | Zindrick Thomas |
President and CEO |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025, and 1,452 shares acquired under the Issuer's Employee Stock Purchase Plan on November 14, 2025. |
Common Stock
|
4,509 |
| 2025-11-17 | Cappello Joseph |
Chief Technical Officer |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025. |
Common Stock
|
973 |
| 2025-11-17 | Smalling Ralph |
Head of Regulatory |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. The total shown in Column 5 takes into account the transactions reported on Forms 4 filed on August 29, 2025 and September 3, 2025. |
Common Stock
|
343 |
| 2025-11-17 | Yu Yong |
SVP, Clinical Development |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. The total shown in Column 5 takes into account the transactions reported on Form 4 filed on August 29, 2025. |
Common Stock
|
973 |
| 2025-09-03 | Smalling Ralph |
Head of Regulatory |
Sell↓
Filing footnotes — Common Stock (Direct)
Represents shares sold by the Reporting Person to cover estimated taxes to be paid by the Reporting Person in connection with the vesting of restricted stock units. The total shown in Column 5 takes into account the transactions reported on Forms 4 filed on August 29, 2025 and September 3, 2025. |
Common Stock
|
580 |
| 2025-09-01 | Zindrick Thomas |
President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. The shares subject to these options are fully vested. |
Stock Option (Right to Buy)
|
925,000 |
| 2025-09-01 | Cappello Joseph |
Chief Technical Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. The shares subject to these options are fully vested. |
Stock Option (Right to Buy)
|
16,666 |
| 2025-09-01 | Zindrick Thomas |
President and CEO |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. The shares subject to these options are fully vested. |
Stock Option (Right to Buy)
|
925,000 |
| 2025-09-01 | Zindrick Thomas |
President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. The shares subject to these options are fully vested. |
Stock Option (Right to Buy)
|
157,372 |
| 2025-09-01 | Yu Yong |
SVP, Clinical Development |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. |
Stock Option (Right to Buy)
|
65,000 |
| 2025-09-01 | Zindrick Thomas |
President and CEO |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. The shares subject to these options are fully vested. |
Stock Option (Right to Buy)
|
23,568 |
| 2025-09-01 | Cappello Joseph |
Chief Technical Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. |
Stock Option (Right to Buy)
|
65,000 |
| 2025-09-01 | Zindrick Thomas |
President and CEO |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. The shares subject to these options are fully vested. |
Stock Option (Right to Buy)
|
23,568 |
| 2025-09-01 | Cappello Joseph |
Chief Technical Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. The shares subject to these options are fully vested. |
Stock Option (Right to Buy)
|
13,333 |
| 2025-09-01 | Cappello Joseph |
Chief Technical Officer |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. The shares subject to these options are fully vested. |
Stock Option (Right to Buy)
|
13,333 |
| 2025-09-01 | Yu Yong |
SVP, Clinical Development |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. The shares subject to the option are fully vested. |
Stock Option (Right to Buy)
|
207,652 |
| 2025-09-01 | Cappello Joseph |
Chief Technical Officer |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. The shares subject to these options are fully vested. |
Stock Option (Right to Buy)
|
80,000 |
| 2025-09-01 | Zindrick Thomas |
President and CEO |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. |
Stock Option (Right to Buy)
|
250,000 |
| 2025-09-01 | Zindrick Thomas |
President and CEO |
Other↓
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. The shares subject to these options are fully vested. |
Stock Option (Right to Buy)
|
157,372 |
| 2025-09-01 | Yu Yong |
SVP, Clinical Development |
Award↑
Filing footnotes — Stock Option (Right to Buy) (Direct)
The transactions reported herein reflect a one-time reduction of the exercise prices of these stock options, effective September 1, 2025, to an exercise price of $3.33 per share, the price of the Issuer's common stock on September 1, 2025. There is no change to the expiration dates or the vesting schedule of the stock options. The shares subject to the option vest as follows: 25% on September 11, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. |
Stock Option (Right to Buy)
|
65,000 |